<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04737291</url>
  </required_header>
  <id_info>
    <org_study_id>drug coated balloon</org_study_id>
    <nct_id>NCT04737291</nct_id>
  </id_info>
  <brief_title>Drug Coated Ballon in Critical Limb Ischemia</brief_title>
  <acronym>DCB</acronym>
  <official_title>Outcomes of Drug Coated Balloon Angioplasty for Femoropopliteal Lesions in Patients With Critical Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and efficacy of drug coated balloon (DCB) for the treatment of&#xD;
      femoropopliteal lesions in patients with critical limb ischemia (CLI)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Critical limb ischemia (CLI) is the most advanced stage of peripheral artery disease (PAD);&#xD;
      which is estimated to affect more than 200 million people worldwide.(1) CLI classified as&#xD;
      Rutherford category (RC) 4-6, includes ischemic rest pain and tissue loss.(2) The first line&#xD;
      revascularization strategy for patients with CLI is endovascular percutaneous transluminal&#xD;
      angioplasty (PTA).(3) The treatment of femoropopliteal lesions displays a huge anatomic&#xD;
      challenge as this segment serves various biomechanical functions, Which makes endovascular&#xD;
      treatment is challenging.(4) Plain balloon (PB) angioplasty for femoropopliteal artery&#xD;
      disease has a high rate of procedural success and an acceptable safety profile, in spite of&#xD;
      initially encouraging technical success after femoropopliteal (PTA), postprocedural&#xD;
      restenosis remains the major challenge(5) Excessive extracellular matrix material synthesized&#xD;
      by activated smooth muscle cells (SMC) in the media of the arteries leads to Neointimal&#xD;
      hyperplasia and restenosis.(6) Restenosis resulting in loss of primary patency, late lumen&#xD;
      loss (LLL), occlusion and/or the need for target lesion revascularization (TLR).(7)&#xD;
      Drug-coated balloons (DCBs) inhibit the neointimal hyperplasia, the biological mechanism of&#xD;
      restenosis formation, by application of cytostatic agents in a local therapeutic&#xD;
      concentration.(8) The antiproliferative paclitaxel (PTX) seems to be the most effective&#xD;
      therapeutic agent for DCBs due to local retention in the arterial wall.(9)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from device- and procedure-related mortality</measure>
    <time_frame>30 days</time_frame>
    <description>mortality related to procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>30 days clinically driven target vessel revascularization</measure>
    <time_frame>30 days</time_frame>
    <description>patency rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>major adverse events as amputation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year clinically driven target vessel revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>patency rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Drug Coated Balloon</condition>
  <arm_group>
    <arm_group_label>Angioplasty by DCB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>angioplasty of stenotic , ocluded or recoil segment using drug coated ballon</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>drug coated balloon</intervention_name>
    <description>use of drug coated balloon in treatment of critical limb ischemia</description>
    <arm_group_label>Angioplasty by DCB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Adults at least 18 years of age with critical lower limb ischemia (Rutherford category&#xD;
             4, 5), stenotic (≥70% by visual angiographic assessment) or occlusive lesions in the&#xD;
             native SFA or PPA, and vessel diameter ≥4 and ≤6 mm were eligible.&#xD;
&#xD;
          -  Total lesion length ≤190 mm (visual angiographic assessment).&#xD;
&#xD;
          -  DE novo angioplasty&#xD;
&#xD;
          -  Recurrent or recoil lesion&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  breast feeding&#xD;
&#xD;
          -  iliac lesions&#xD;
&#xD;
          -  Malignancy&#xD;
&#xD;
          -  Patients with raised renal chemistry.&#xD;
&#xD;
          -  Patients with contraindication to antiplatelet therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hassan bakr, professor</last_name>
    <role>Study Chair</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>mahmoud ismael, ass profesor</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>osman mahmoud, lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ahmed nageeb, master</last_name>
    <phone>01096192891</phone>
    <email>a7mednageeb@aun.edu.eg</email>
  </overall_contact>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed Nageeb</investigator_full_name>
    <investigator_title>doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

